5 Key Takeaways

• 1

  Ninerafaxstat may be safe and effective for patients with nonobstructive hypertrophic cardiomyopathy.

• 2

  Hypertrophic cardiomyopathy increases the risk of sudden cardiac death and complicates heart function.

• 3

  The phase II IMPROVE-HCM trial involved 67 patients and showed no significant adverse events from ninerafaxstat.

• 4

  Patients receiving ninerafaxstat experienced reductions in left atrial size and improvements in symptoms.

• 5

  A larger phase III trial may be necessary to further evaluate ninerafaxstat's efficacy in this population.